Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy

Autor(es)

Patente, Thiago A. ^[1] ; Pinho, Mariana P. ^[1] ; Oliveira, Aline A. ^[1] ; Evangelista, Gabriela C. M. ^[1] ; Bergami-Santos, Patricia C. ^[1] ; Barbuto, Jose A. M. ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Lab Tumor Immunol, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Dept Med, Discipline Mol Med, Fac Med, Sao Paulo - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: FRONTIERS IN IMMUNOLOGY; v. 9, JAN 21 2019.
• Citações Web of Science: 6

Resumo

Dendritic cells (DC) are professional antigen presenting cells, uniquely able to induce naive T cell activation and effector differentiation. They are, likewise, involved in the induction and maintenance of immune tolerance in homeostatic conditions. Their phenotypic and functional heterogeneity points to their great plasticity and ability to modulate, according to their microenvironment, the acquired immune response and, at the same time, makes their precise classification complex and frequently subject to reviews and improvement. This review will present general aspects of the DC physiology and classification and will address their potential and actual uses in the management of human disease, more specifically cancer, as therapeutic and monitoring tools. New combination treatments with the participation of DC will be also discussed. (AU)

• Processo FAPESP: 14/25988-1 - Análise do repertório de Linfócitos T em pacientes com câncer: desvendando a resposta imune antitumoral em humanos
• Beneficiário: Mariana Pereira Pinho
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 16/01137-8 - Análise do repertório de linfócitos T específicos para antígenos tumorais em doadores saudáveis utilizando bibliotecas de linfócitos T
• Beneficiário: Mariana Pereira Pinho
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Doutorado
• Processo FAPESP: 14/26437-9 - Efeito da glicose e da albumina glicada sobre células dendríticas derivadas de monócitos (mo-DCs) de doadores saudáveis e de pacientes portadores de diabetes mellitus tipo 1
• Beneficiário: Thiago Andrade Patente
• Modalidade de apoio: Bolsas no Brasil - Doutorado